Storia in 1 fonti

NeuroScientific locks in key US FDA meeting

NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.

Raccontata da

smh.com.au

Timeline cronologica

giovedì 13 agosto 2026·smh.com.au
NeuroScientific locks in key US FDA meeting
NeuroScientific has locked in a key meeting with the US FDA for its StemSmart technology aimed at treating refractory Crohn’s disease in a planned Phase 2 trial.